Platelet membrane-camouflaged bioactive glass nano-formulations for enhanced drug delivery in the treatment of acute arterial thrombosis
Source abstract
Abstract
Thrombus treatment remains a significant challenge, primarily due to factors such as the short half-life of thrombolytic agents, suboptimal drug utilization, and limited therapeutic efficacy. In this study, we developed a platelet membrane-camouflaged bioactive glass nanoparticles (BGs) as drug carriers to load thrombolytic agent urokinase (UK) and anticoagulant drug tirofiban (TF). UK and TF were firstly incorporated onto BGs, and followed by a camouflage of polydopamine (PDA) and platelet membrane (PM) to form composite nano-formulation (TUBGs@PP). This composite nano-formulation leverages the PM camouflage to enhance its biocompatibility, prolong circulation time in vivo, and extend the half-life of drugs. Additionally, as-fabricated TUBGs@PP composite nano-formulation can circumvent immune system-mediated clearance, thereby facilitating targeted drug delivery to the thrombus sites and enhancing the thrombolytic efficacy. In vivo results demonstrated that the TUBGs@PP composite nano-formulations not only prolonged circulation time but also effectively unclogged blood vessels at the site of thrombosis, while reducing recurrence of thrombosis and drug side effects. STATEMENT OF SIGNIFICANCE: The platelet membrane-camouflaged bioactive glass nanoparticles as drug carriers for the synergistic co-delivery of urokinase and tirofiban have been developed (TUBGs@PP) for the treatment of acute arterial thrombosis. This cutting-edge therapeutic strategy addresses several critical limitations inherent in current thrombolytic treatments, including the transient half-life of thrombolytic agents, suboptimal drug bioavailability, and limited therapeutic efficacy. In vivo studies demonstrate that TUBGs@PP not only achieves sustained circulation but also effectively restores vascular patency at thrombotic loci, concurrently reducing the risk of thrombotic recurrence and minimizing adverse drug effects. This study highlights the paradigm-shifting potential of TUBGs@PP in thrombolytic therapy, offering a transformative solution to existing challenges and promising to markedly improve clinical outcomes for patients.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Medical and Biological Ozone Research · Laser-Ablation Synthesis of Nanoparticles
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Heart disease and strokes tatistics—2019 update: a report from the American heart association
2. Economic burden of cardiovascular diseases in the enlarged European Union10.1093/eurheartj/ehi733 ↗
3. Mechanis of disease: mechanis of thrombus formation10.1056/NEJMra0801082 ↗
4. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate?10.1055/s-0036-1597560 ↗
5. Complement, inflammation and thrombosis10.1111/bph.15476 ↗
6. Riete Investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism10.1160/TH13-02-0132 ↗
7. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment10.1016/S1474-4422(13)70101-7 ↗
8. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin10.1016/j.biomaterials.2017.11.047 ↗
9. Platelet-covered nanocarriers for targeted delivery of hirudin to eliminate thrombotic complication in tumor therapy10.1021/acsnano.2c06666 ↗
10. Biological mediator-propelled nanosweeper for nonpharmaceutical thrombus therapy10.1021/acsnano.0c09939 ↗
11. Nanomedicine progress in thrombolytic therapy10.1016/j.biomaterials.2020.120297 ↗
12. Erythrocyte membrane-coated invisible acoustic-sensitive nanoparticle for inducing tumor thrombotic infarction by precisely damaging tumor vascular endothelium10.1002/smll.202201933 ↗
13. Application of nanotechnology in thrombus therapy10.1002/adhm.202202578 ↗
14. Emerging nanotherapeutics for antithrombotic treatment10.1016/j.biomaterials.2020.120200 ↗
15. Cryo-shocked platelet coupled with ROS-responsive nanomedicine for targeted treatment of thromboembolic disease10.1021/acsnano.2c11865 ↗
16. Nanotherapeutic delivers clot-busting drug10.1038/nrd3828 ↗
17. Nitric oxide-driven nanomotors with bowl-shaped mesoporous silica for targeted thrombolysis10.1016/j.jcis.2021.12.065 ↗
18. Targeted thrombolytic therapy with metal organic-framework-derived carbon based platfor with multimodal capabilities10.1021/acsami.1c03134 ↗
19. Red blood cell membrane-coated functionalized Cu-doped metal organic framework nanoformulations as a biomimetic platform for improved chemo-/chemodynamic/photothermal synergistic therapy10.1016/j.ijpharm.2024.123811 ↗
20. Engineering white blood cell membrane-camouflaged nanocarriers for inflammation-related therapeutics
21. Protease-loaded CuS nanoparticles with synergistic photothermal/dynamic therapy against F. nucleatum-induced periodontitis10.1021/acsami.3c04534 ↗
22. Red blood cell membrane-camouflaged poly (lactic-co-glycolic acid) microparticles as a potential controlled release drug delivery system for local stellate ganglion microinjection10.1016/j.actbio.2023.02.030 ↗
23. Engineered nanoplatelets for targeted delivery of plasminogen activators to reverse thrombus in multiple mouse thrombosis models
24. Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology10.1016/j.biomaterials.2024.122670 ↗
25. Platelet membrane-functionalized hollow mesoporous prussian blue nanomedicine for comprehensive thrombolytic management by targeted enhanced fibrinolysis and ROS scavenging
26. Biomimetic platelet-camouflaged drug-loaded polypyrrole for the precise targeted antithrombotic therapy10.1186/s12951-023-02197-3 ↗
27. Platelets and platelet adhesion molecules: novel mechanis of thrombosis and anti-thrombotic therapies10.1186/s12959-016-0100-6 ↗
28. Platelet metabolism meets thrombosis10.1182/blood-2018-08-865600 ↗
29. Thrombosis and platelets: an update
30. GOx-powered janus platelet nanomotors for targeted delivery of thrombolytic drugs in treating thrombotic diseases10.1021/acsbiomaterials.3c00387 ↗
31. Editorial: the mechanism and prevention of platelet adhesion and aggregation considered in relation to arterial thrombosis10.1182/blood.V24.3.309.309 ↗
32. Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice10.1126/sciadv.abd0130 ↗
33. Porous bioactive glass micro- and nanospheres with controlled morphology: developments, properties and emerging biomedical applications10.1039/D0MH01498B ↗
34. Red blood cell membrane-camouflaged polydopamine and bioactive glass composite nanoformulation for combined chemo/chemodynamic/photothermal therapy10.1021/acsbiomaterials.3c01239 ↗
35. Biomimetic platelet membrane-coated nanoparticles for targeted therapy10.1016/j.ejpb.2022.01.004 ↗
36. Multi-functional platelet membrane-camouflaged nanoparticles reduce neuronal apoptosis and regulate microglial phenotype during ischemic injury
37. Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy10.1016/j.jconrel.2020.08.030 ↗
38. Platelet membrane-coated r-SAK improves thrombolytic efficacy by targeting thrombus10.1021/acsami.3c18402 ↗
39. Transdermal delivery of Cu-doped polydopamine using microneedles for photothermal and chemodynamic synergistic therapy against skin melanoma10.1016/j.cej.2021.130790 ↗
40. Superhydrophilic versus normal polydopamine coating: a superior and robust platform for synergistic antibacterial and antithrombotic properties10.1016/j.cej.2020.126196 ↗
41. Near-infrared triggered release of uPA from nanospheres for localized hyperthermia-enhanced thrombolysis10.1002/adfm.201701824 ↗
42. Near-infrared light activated thermosensitive ion channel to remotely control transgene system for thrombolysis therapy
43. Platelet-derived drug delivery syste: pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond10.1016/j.biomaterials.2024.122478 ↗
44. Thrombosis-responsive thrombolytic coating based on thrombin-degradable tissue plasminogen activator (t-PA) nanocapsules10.1002/adfm.201703934 ↗
45. Cell membrane-camouflaged inorganic nanoparticles for cancer therapy10.1186/s12951-022-01475-w ↗
46. Qing Jiang, Xingquan Xu, and Dongquan Shi platelet-derived porous nanomotor for thrombus therapy10.1126/sciadv.aaz9014 ↗
47. Bio-inspired bioactive glasses for efficient microRNA and drug delivery10.1039/C7TB01021D ↗
48. Platelet membrane cloaked nanotubes to accelerate thrombolysis by thrombus clot-targeting and penetration
49. A erythrocyte-platelet hybrid membrane coated biomimetic nanosystem based on ginsenosides and PFH combined with ultrasound for targeted delivery in thrombus therapy10.1016/j.colsurfb.2023.113468 ↗
50. Multifunctional core/satellite polydopamine@Nd3+-sensitized upconversion nanocomposite: a single 808 nm near-infrared light-triggered theranostic platform for in vivo imaging-guided photothermal therapy10.1007/s12274-017-1555-x ↗
51. Nanoassemblies of self-immolative boronate-bridged retinoic acid dimeric prodrug as a clot-targeted self-deliverable antithrombotic nanomedicine10.1021/acsnano.3c01503 ↗
52. Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis10.1016/j.actbio.2018.01.038 ↗
53. Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats10.1016/j.ejphar.2017.11.026 ↗
54. Nanogold flower-inspired nanoarchitectonics enables enhanced light-to-heat conversion ability for rapid and targeted chemo-photothermal therapy of a tumor
55. Free-blockage mesoporous silica nanoparticles loaded with cerium oxide as ROS-responsive and ROS-scavenging nanomedicine
56. Urokinase loaded black phosphorus nanosheets for sequential thrombolysis and reactive oxygen species scavenging in ischemic stroke treatment10.1039/D2BM00746K ↗
57. Deep vein thrombosis diagnosis with d-Dimer adjusted to cinical probability10.1182/blood-2020-140416 ↗
58. Salvatore Santo Signorelli. Direct oral anticoagulant treatment of deep vein thrombosis reduces IL‑6 expression in peripheral mono‑nuclear blood cells10.3892/etm.2020.9367 ↗
59. Monocyte toll-like receptor 4 (tlr4) signaling is essential for post thrombotic upa expression